Down 28% in a year while the S&P 500 rose 12%; up 204% over three years.
−3Long-term trend
ADMA's Quality Score fell 1 point on Wed, Nov 4, to 1.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Since its 2025 high | Down 55% |
| Latest filing | 8-K, Nov 4 |
ReportToday after the close: sales of $141.1M; a profit of $0.22 a share. Raised its outlook for the year. Past reports ›
After hoursADMA Biologics reported quarterly revenue of $141.1 million and diluted EPS of $0.22
Expected to report Wed Feb 24, after the close
ADMA is #124 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 124 |
Share count against a year before: ADMA -5.5%, RXRX +28%, RGEN +0.3%.
Expected to report Wed Feb 24, after the close (in 112 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $141.1M, 5% more than a year ago; a profit of $0.22 a share, from $0.15.
“Margin expansion reflected favorable ASCENIV product mix and the continued benefits of the Company's yield-enhanced manufacturing process.”
ADMA's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Adjusted net income | at least $180 million |
Sales grew 49% a year over 3 years, fiscal 2022 to 2025.
Its share count grew 7.4% a year over 3 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 5, 2026 | +4.8% | +8.6% | +5.6% |
| May 6, 2026 | -25.4% | -16.0% | -15.7% |
| Feb 25, 2026 | +3.6% | -3.2% | +5.5% |
Sales grew every year from 2020 to 2025, to $510M. It made a profit in two of the six years.
One insider bought $251K across 3 filings in the last 6 months. No open-market sales on record. The newest:
4 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ADMA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
“The plasma products industry is highly competitive.”
ADMA scores 1 today, which Breakaway calls Below Average. It is #124 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 28% in a year while the S&P 500 rose 12%; up 204% over three years. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ADMA scores 1 today, which Breakaway calls Below Average (0 to 5). That is #124 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ADMA's 1.
One insider bought $251K across 3 filings in the last 6 months. No open-market sales on record. The newest is Jerrold B. Grossman, Director, who bought $51K on May 27. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.